Stock Research: Cohance Lifesciences

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

Cohance Lifesciences

XNSE:543064 INE03QK01018
60
  • Value
    47
  • Growth
    85
  • Safety
    Safety
    3
  • Combined
    32
  • Sentiment
    66
  • 360° View
    360° View
    60
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

Cohance Lifesciences Limited, formerly Suven Pharmaceuticals Limited, is an India-based technology-driven contract development and manufacturing organization (CDMO), providing integrated solutions in custom synthesis, process research and development (R&D), and manufacturing. The Company’s business units include pharmaceutical CDMO, specialty chemical CDMO, and active pharmaceutical ingredient (API) (including formulations). Its integrated CDMO model enables comprehensive molecule development and life cycle management for both pharmaceutical and specialty chemical partners. Its custom synthesis services include design and synthesis, synthesis of complex molecules, synthesis of reference standards, synthesis of impurities and metabolites, scale-up of existing synthetic routes, and process optimization and backward integration. Its process research services include route scouting, process development, process safety evaluation, analytical method development, and regulatory support.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 60 (better than 60% compared with alternatives), overall professional sentiment and financial characteristics for the stock Cohance Lifesciences are above average. The 360° View is based on consolidating four consolidated indicators, with half of the metrics below and half above average for Cohance Lifesciences. The consolidated Growth Rank has a good rank of 85, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. This means that growth is higher than for 85% of competitors in the same industry. The consolidated Sentiment Rank also has a good rank of 66, which means that professional investors are more optimistic about the stock than for 66% of alternative investment opportunities. But the consolidated Value Rank has a less desirable rank of 3, which means that the share price of Cohance Lifesciences is on the higher side compared with typical size in indicators such as revenues, profits, and invested capital. This means the stock price is higher than for 97% of alternative stocks in the same industry. Finally, the consolidated Safety Rank has a riskier rank of 47, which means that the company has a financing structure that is riskier than those of 53% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. ...read more

more
Index
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 21-Aug-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Growth
Shows a company's growth potential.
High Growth Tough Times
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
3 1 3 15
Growth
85 91 99 71
Safety
Safety
47 51 57 33
Sentiment
66 91 63 47
360° View
360° View
60 69 67 23
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
97 100 100 97
Opinions Change
10 97 50 50
Pro Holdings
n/a 90 45 4
Market Pulse
91 30 21 39
Sentiment
66 91 63 47
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
3 1 3 15
Growth
85 91 99 71
Safety Safety
47 51 57 33
Combined
32 39 61 11
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
13 7 31 43
Price vs. Earnings (P/E)
9 7 1 6
Price vs. Book (P/B)
15 10 19 28
Dividend Yield
8 1 1 23
Value
3 1 3 15
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
96 100 91 60
Profit Growth
98 92 44 42
Capital Growth
52 9 87 98
Stock Returns
43 100 83 39
Growth
85 91 99 71
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
48 76 72 50
Refinancing
5 24 34 26
Liquidity
58 60 76 57
Safety Safety
47 51 57 33

Similar Stocks

Discover high‑ranked alternatives to Cohance Lifesciences and broaden your portfolio horizons.

Kalbe Farma

IDX:KLBF
Country: Indonesia
Industry: Pharmaceuticals
Size: Medium
Full Stock Analysis

Cipla

NSEI:CIPLA
Country: India
Industry: Pharmaceuticals
Size: Large
Full Stock Analysis

L&T Finance Holdings

BSE:533519
Country: India
Industry: Other Financial Services
Size: Medium
Full Stock Analysis

Bosch

BSE:500530
Country: India
Industry: Auto Parts & Equipment
Size: Medium
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.